Side-by-side · Research reference

TirzepatidevsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Tirzepatide

Vilon

Primary target

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Immune cell differentiation pathways, chromatin modification

Pathway

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Unknown — no HPA/HPG axis data

Origin

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Tirzepatide

Vilon

Standard dose (T2D)

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

—

Standard dose (weight)

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

—

Titration schedule

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Mouse / in vitro only

Duration

Indefinite for chronic indication

Not characterised in humans

Reconstitution

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

—

Timing

Once weekly, any time of day

—

Half-life

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Not published — dipeptides typically <10 min plasma t½

Standard dose

—

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Frequency

—

Unknown — literature does not specify chronic administration protocols

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

Tirzepatide

Vilon

GI symptoms

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

—

Injection site reaction

Mild erythema, pruritus

—

Pancreatitis risk

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

—

Hypoglycemia

Low as monotherapy; risk with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

Contraindicated

—

Diabetic retinopathy

Rapid glycemic improvement may transiently worsen

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Tirzepatide

Vilon

1. Reconstitution / device

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Once weekly, same day. Day change allowed if ≥3 days separate doses.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

Pen-supplied. Research vial: 27–31G insulin syringe.

—

06Stack Synergy

Tirzepatide

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020